Accentrix Solution for Injection

Accentrix Solution for Injection

Accentrix is a high-potency ophthalmic intervention containing Ranibizumab (10 mg/ml), a specialized recombinant humanized monoclonal antibody fragment. Specifically engineered for the clinical management of neovascular (wet) age-related macular degeneration (AMD) and other retinal vascular disorders, Accentrix works by targeting the biological drivers of abnormal blood vessel growth. Ranibizumab acts as a potent vascular endothelial growth factor (VEGF) inhibitor, specifically binding to the receptor-binding site of active forms of VEGF-A. This targeted biochemical action provides a decisive therapeutic response to suppress the leakage of fluid and blood into the retina, effectively reducing macular edema and stabilizing or improving visual acuity in patients with sight-threatening conditions.

Key Features

• Specifically binds to and neutralizes VEGF-A to prevent the growth of leaky, abnormal blood vessels.
• Effectively resolves the swelling in the central part of the retina to restore visual clarity.
• Clinically proven to stabilize vision and, in many cases, provide significant gains in letter-reading ability.
• Formulated for direct injection into the vitreous cavity for localized therapeutic action.
• The small antibody fragment size allows for efficient penetration through the retinal layers.

Key Ingredients

• Ranibizumab (10 mg/ml)
• α,α-Trehalose Dihydrate
• L-Histidine
• Polysorbate 20
• Water for Injection

Precautions

• Must be administered only by a qualified ophthalmologist experienced in intravitreal injections.
• Intravitreal injections are associated with a risk of endophthalmitis (serious eye infection); report any pain, redness, or light sensitivity immediately.
• Transient increases in eye pressure are common after injection; your specialist will monitor this during the procedure.
• There is a small risk of retinal tears or detachment following the procedure; any sudden “floaters” or flashes of light require urgent evaluation.
• Consult your healthcare professional before use, as systemic exposure, though low, should be minimized.
• Do not drive or operate machinery immediately after injection, as your vision may be temporarily blurred or pupils may be dilated.

How to Use

• Accentrix is administered as a single intravitreal injection into the affected eye under sterile conditions.
• Local anesthetic drops or a small injection will be used to ensure the procedure is comfortable and pain-free.
• Typically administered once a month initially, with the interval adjusted based on visual acuity and anatomical outcomes (Pro Re Nata or Treat-and-Extend protocols).
• Use any prescribed antibiotic or anti-inflammatory eye drops exactly as directed by your surgeon.
• Regular follow-up appointments involving Optical Coherence Tomography (OCT) scans are mandatory to track the treatment’s progress.
• Avoid rubbing your eye or exposing it to contaminated water (swimming pools/hot tubs) for several days following the injection.

Legal Disclaimer: Accentrix Solution for Injection is a prescription-only pharmaceutical product. Individual results may vary based on the duration and severity of the retinal condition. This product is not intended for the treatment of non-vascular eye diseases. This information is for educational purposes and is not a substitute for professional medical consultation from a retina specialist.